Claims
| Claim | Type | Assessment | Score | Review checks | References |
|---|---|---|---|---|---|
| In the phase II randomized RIO trial of 68 adult men living with HIV who interrupted ART, long-acting 3BNC117-LS and 10-1074-LS delayed viral rebound: median ART restart was 45.4 weeks with antibodies versus 4.6 weeks with placebo, and intact proviruses declined in the antibody arm. | QUANTITATIVE | Supported | 0.9468 | 1 of 4 | 99 |